Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Bentink, Stefan ^a,d   Haibe Kains, Benjamin ^a,d   Risch, Thomas ^a   Fan, Jian Bing ^b   Hirsch, Michelle S ^c,e   Holton, Kristina ^a   Rubio, Renee ^a   April, Craig ^b   Chen, Jing ^b   Wickham Garcia, Eliza ^b   Liu, Joyce ^a,e   Culhane, Aedin ^a,d   Drapkin, Ronny ^a,c,e   Quackenbush, John ^a,d   Matulonis, Ursula A ^a,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ILLUMINA INC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ALGORITHM; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CELL ADHESION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; GENE SET ENRICHMENT ANALYSIS; GENETIC ANALYSIS; HUMAN; ISIS CLASS DISCOVERY ALGORITHM; MAJOR CLINICAL STUDY; OVARY CANCER; SEROUS OVARIAN CANCER; TUMOR VASCULARIZATION; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; SURVIVAL RATE;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL ADHESION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RNA, MESSENGER; SURVIVAL RATE;

EID: 84863139258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030269     Document Type: Article

References (40)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6.
2. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200.
3. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, et al. (2005) Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3696.
4. De Smet F, Pochet NL, Engelen K, Van Gorp T, Van Hummelen P, et al. (2006) Predicting the clinical behavior of ovarian cancer from gene expression profiles. Int J Gynecol Cancer 16 (Suppl 1): 147-151.
5. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525.
6. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, et al. (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11: 2149-2155.
7. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, et al. (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11: 6300-6310.
8. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, et al. (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23: 7911-7918.
9. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700-4710.
10. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
11. Wong KK, Cheng RS, Mok SC, (2001) Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30: 670-675.
12. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, et al. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
13. Liu JF, Hirsch MS, Lee H, Matulonis UA, (2009) Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol 115: 401-406.
14. Clauss A, Ng V, Liu J, Piao H, Russo M, et al. (2010) Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia 12: 161-172.
15. von Heydebreck A, Huber W, Poustka A, Vingron M, (2001) Identifying splits with clear separation: a new class discovery method for gene expression data. Bioinformatics 17 (Suppl 1): S107-114.
16. April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, et al. (2009) Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS ONE 4: e8162.
17. Chen J, Lozach J, Garcia EW, Barnes B, Luo S, et al. (2008) Highly sensitive and specific microRNA expression profiling using BeadArray technology. Nucleic Acids Res 36: e87.
18. Du P, Kibbe WA, Lin SM, (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548.
19. Lin SM, Du P, Huber W, Kibbe WA, (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36: e11.
20. Tibshirani R, Hastie T, Narasimhan B, Chu G, (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572.
21. Ruschhaupt M, Huber W, Poustka A, Mansmann U, (2004) A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol 3: Article37.
22. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. Journal of Clinical Oncology 25: 517-525.
23. Crijns APG, Fehrmann RSN, de Jong S, Gerbens F, Meersma GJ, et al. (2009) Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer. PLoS Medicine 6: e1000024.
24. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clinical Cancer Research 14: 5198-5208.
25. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, et al. (2010) Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PloS one 5: e9615.
26. Denkert C, Budczies J, Darb-Esfahani S, Gyorffy B, Sehouli J, et al. (2009) A prognostic gene expression index in ovarian cancer- validation across different independent data sets. J Pathol 218: 273-280.
27. Culhane AC, Schwarzl T, Sultana R, Picard KC, Picard SC, et al. (2010) GeneSigDB-a curated database of gene expression signatures. Nucleic Acids Res 38: D716-725.
28. Haibe-Kains B, Culhane AC, Desmedt C, Bontempi G, Quackenbush J, et al. (2011) A three-gene model to robustly identify breast cancer molecular subtypes. submitted.
29. Kapp A, Jeffrey S, Langerod A, Borresen-Dale A-L, Han W, et al. (2006) Discovery and validation of breast cancer subtypes. BMC genomics 7: 231.
30. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI, (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165-5171.
31. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186.
32. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, et al. (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27: 5601-5606.
33. Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, et al. (2010) Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 28 suppl; abstr LBA1.
34. Aghajanian C, Finkler NJ, Rutherford T, Smith DA, Yi JY, et al. (2011) OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 29.
35. Perren T, Ledermann JA, Gourley C, Essapen S, Rustin G, et al. (2010) Results of ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 21.
36. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, et al. (2010) Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS ONE 5: e9615.
37. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486.
38. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, et al. (2008) Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 105: 7004-7009.
39. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, et al. (2009) Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6: e24.
40. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, et al. (2009) A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16: 521-532.